Fig. 1From: Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative studyCumulative incidence of CNS progression (a) in all eligible patients (n = 279); b patients without cerebral metastasis prior to EGFR-TKIs first-line treatment; c patients cerebral metastasis prior to EGFR-TKIs first-line treatmentBack to article page